Diabetic Neuropathy Market to Surpass USD 2.8 Billion Baseline by 2034 Across the 7MM, Driven by Emerging Gene and Non-Opioid Therapies

The Diabetic Neuropathy treatment landscape across the seven major markets (7MM) is poised for substantial transformation over the next decade. According to a recent analysis by DelveInsight, the total Diabetic Neuropathy Market Size stood at approximately USD 2,800 million in 2023 and is projected to expand significantly by 2034 during the study period (2020–2034).

United States Leads the Global Market with ~80% Share

Among the 7MM, the United States dominated the Diabetic Neuropathy market in 2023, accounting for nearly 80% of the total market share. The strong commercial presence of approved therapies, high disease awareness, favorable reimbursement structures, and robust healthcare infrastructure have collectively positioned the US as the largest revenue contributor.

Within the European region, the UK accounted for the largest market size among EU4 and the UK, while Spain represented the smallest share in 2023. Germany, however, reported the highest number of diagnosed prevalent cases among EU4 and the UK, highlighting a significant patient burden and untapped therapeutic opportunity.

Disease Burden and Epidemiological Trends

Diabetic Neuropathy remains one of the most common microvascular complications of diabetes mellitus. After 20 years of disease progression, more than 50% of diabetes patients are affected by neuropathic complications, often characterized by chronic pain in the lower extremities, significantly impairing quality of life.

As noted by the American Diabetes Association, chronic distal symmetric polyneuropathy (DSPN) accounts for approximately 75% of all diabetic neuropathies, making it the most prevalent subtype.

In 2023, the United States accounted for the highest number of diagnosed prevalent cases across the 7MM, contributing roughly 60% of the total diagnosed cases. Type-specific analysis indicates that peripheral diabetic neuropathy constituted approximately 60% of total cases in the US, making it the dominant subtype in clinical settings.

Among EU4 and the UK, Germany reported the highest number of total diagnosed prevalent cases, whereas Spain had the lowest burden.

Market Drivers Accelerating Growth

The diabetic neuropathy market is witnessing growth driven by several key factors:

Rising Prevalence of Diabetes:
The global surge in diabetes incidence directly correlates with increased neuropathy cases, expanding the addressable patient population.

Growing Geriatric Population:
Older individuals are at greater risk of neuropathy complications, driving sustained demand for pain management therapies.

Advancements in Diagnostics:
Improved diagnostic tools such as nerve conduction studies, quantitative sensory testing (QST), and high-frequency ultrasound are enhancing early detection rates and minimizing misdiagnosis.

Therapeutic Innovations:
The emergence of disease-modifying and non-opioid pain management therapies is expected to redefine the treatment paradigm.

Healthcare Infrastructure Expansion:
Improved access to care, particularly in developed economies, supports increased diagnosis and treatment rates.

Favorable Reimbursement Policies:
Insurance coverage and evolving clinical guidelines encourage greater adoption of approved therapies.

Digital Health Integration:
Telemedicine and remote monitoring solutions are enhancing long-term disease management strategies.

Current Treatment Landscape: Symptom Management Dominates

At present, no therapy can reverse diabetic neuropathy or halt disease progression definitively. Treatment strategies focus on two primary goals:

1. Preventing nerve fiber loss by targeting underlying pathophysiological mechanisms.
2. Providing symptomatic relief from painful diabetic neuropathy (DPN).

Clinical guidelines recommend first-line use of tricyclic antidepressants (TCAs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and γ-aminobutyric acid (GABA) analogs such as gabapentin and pregabalin. Opioids and topical treatments are generally considered second-line options.

In 2023, NSAIDs accounted for the largest share in the current market, while NUCYNTA ER (extended-release tapentadol) emerged as the second-highest revenue generator.

Approved therapies across the 7MM include:

• Duloxetine (SNRI)
• Pregabalin (GABA analog)
• Extended-release tapentadol (US-approved opioid)
• TARLIGE (mirogabalin) in Japan
• QUTENZA (capsaicin 8% topical system)

Spotlight on QUTENZA: A Non-Systemic Topical Option

QUTENZA, developed by Grünenthal and commercialized in the US by Averitas Pharma, is an 8% capsaicin topical patch designed to treat neuropathic pain associated with DPN of the feet.

In July 2020, QUTENZA received US FDA approval for adult patients with diabetic peripheral neuropathy. The therapy works as a TRPV1 receptor agonist, initially stimulating nociceptive nerve fibers followed by prolonged pain relief due to reduced TRPV1-expressing nerve endings.

Emerging Therapies Set to Transform the Market

A wave of innovative pipeline candidates is expected to significantly impact the Diabetic Neuropathy treatment landscape during the forecast period (2024–2034).

ENGENSIS/VM202 (donaperminogene seltoplasmid) – Developed by Helixmith, this first-in-class plasmid DNA gene therapy expresses hepatocyte growth factor (HGF) to stimulate angiogenesis and nerve regeneration. It received RMAT designation from the US FDA in 2018 for its potential angio-neurorestorative effects.

LX9211 – From Lexicon Pharmaceuticals, this oral small molecule AAK1 inhibitor has demonstrated promising results in neuropathic pain models and has received Fast Track Designation for diabetic peripheral neuropathic pain.

VX-548 – Being developed by Vertex Pharmaceuticals, this investigational therapy is expected to provide a non-opioid pain management alternative with differentiated efficacy.

Other candidates such as sublingual Cannabidiol (CBD) and additional regenerative approaches are also under investigation.

By 2034, LX9211 is projected to capture the largest market share among emerging therapies across the 7MM.

Market Outlook Through 2034

The Diabetic Neuropathy market outlook remains optimistic, supported by pipeline innovations and increasing disease awareness. However, challenges persist, including:

• Delays in diagnosis

• Serious long-term complications

• Economic burden on healthcare systems

• Limited understanding of disease progression

• Lack of curative treatment options

Prevention remains central to diabetes care, emphasizing glucose control and lifestyle modifications. Although glycemic management can prevent progression, it has limited impact on symptom reversal once neuropathy is established.

Comprehensive Report Coverage

DelveInsight’s Diabetic Neuropathy Treatment Market Report (2020–2034) offers:

• Detailed epidemiology segmentation (prevalent, type-specific, diagnosed, treated cases)

• Historical and forecasted market size analysis

• Therapy-wise market share breakdown

• SWOT and Conjoint Analysis

• KOL insights from 10+ experts across the 7MM

• Drug pipeline analysis (Phase II & III)

• Reimbursement and market access evaluation

• Patient journey mapping

• Cross-competition analysis

The report also provides 11-year forecasts and evaluates the impact of emerging therapies such as VM202, VX-548, and LX9211 on the competitive landscape.

Unlock the Full Market Potential

As innovative gene therapies, non-opioid analgesics, and targeted molecular treatments approach commercialization, the Diabetic Neuropathy treatment market is expected to undergo a structural shift by 2034.

Stakeholders, investors, pharmaceutical companies, and healthcare strategists seeking a competitive edge can request to unlock the sample pages of the comprehensive “Diabetic Neuropathy Treatment Market” report for in-depth insights into market dynamics, epidemiology forecasts, reimbursement frameworks, and emerging therapy positioning.

With a strong baseline of USD 2.8 billion in 2023 and transformative pipeline advancements underway, the Diabetic Neuropathy market across the 7MM stands at the cusp of significant growth and innovation over the next decade.